Circadian Technologies is now focused on developing VGX-100, a VEGF-C inhibitory monoclonal antibody. Trials will start in late 2011. If safety studies complete as expected, VGX-100 is scheduled to enter a Phase II trial in glioblastoma as an adjuvant to Avastin. Preclinical data suggests a strong synergistic action. The other lead product, IMC-3C5, is in Phase I licensed to ImClone (Lilly). Circadian has a strong IP position that might be a short-term revenue source if major phama companies start VEGF-C projects. Two niche diagnostics will start generating sales.
For further information please download PDF below:
